|
|
Article: Intercept Pharmaceuticals Announces Completion of First Financing Round; - Acquires Portfolio of Novel FXR Compounds for Treatment of Liver and Metabolic Diseases -.
- Article from:
- PR Newswire
- Article date:
- August 26, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK, Aug. 26 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on developing small molecule drugs for the treatment of chronic liver and metabolic diseases, today announced completion of a first round of financing that raised a total of $3 million. The financing was managed by Joseph Stevens and Company.
Intercept has used a portion of the financing proceeds to complete acquisition of its lead compound, the FXR nuclear receptor agonist INT-747, and associated intellectual property covering a portfolio of FXR compounds invented by Intercept scientific co-founder Roberto Pellicciari, Ph.D., Professor of ...
Related newspaper, magazine, and journal articles:
|
|
Article: Intercept Pharmaceuticals Expands Senior Management ...
PR Newswire;
May 21, 2007 ;
700+ words
... ... PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical ... reporting directly to Mark Pruzanski, M.D., Intercept ... College. About Intercept Pharmaceuticals New York City-based Intercept Pharmaceuticals, Inc. is a clinical ...
|
|